1
|
Victor RG, Li N, Blyler CA, Mason OR, Chang LC, Moy NPB, Rashid MA, Weiss JP, Handler J, Brettler JW, Sagisi MB, Rader F, Elashoff RM. Nocturia as an Unrecognized Symptom of Uncontrolled Hypertension in Black Men Aged 35 to 49 Years. J Am Heart Assoc 2020; 8:e010794. [PMID: 30827133 PMCID: PMC6474941 DOI: 10.1161/jaha.118.010794] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Background Hypertension is assumed to be asymptomatic. Yet, clinically significant nocturia (≥2 nightly voids) constitutes a putative symptom of uncontrolled hypertension. Black men with hypertension may be prone to nocturia because of blunted nocturnal blood pressure (BP) dipping, diuretic drug use for hypertension, and comorbidity that predisposes to nocturia. Here, we test the hypothesis that nocturia is a common and potentially reversible symptom of uncontrolled hypertension in black men. Methods and Results We determined the strength of association between nocturia (≥2 nightly voids) and high BP (≥135/85 mm Hg) by conducting in‐person health interviews and measuring BP with an automated monitor in a large community‐based sample of black men in their barbershops. Because nocturia is prevalent and steeply age‐dependent after age 50 years, we studied men aged 35 to 49 years. Among 1673 black men (mean age, 43±4 years [SD]), those with hypertension were 56% more likely than men with normotension to have nocturia after adjustment for diabetes mellitus and sleep apnea (adjusted odds ratio, 1.56; 95% CI, 1.25–1.94 [P<0.0001]). Nocturia prevalence varied by hypertension status, ranging from 24% in men with normotension to 49% in men whose hypertension was medically treated but uncontrolled. Men with untreated hypertension were 39% more likely than men with normotension to report nocturia (P=0.02), whereas men whose hypertension was treated and controlled were no more likely than men with normotension to report nocturia (P=0.69). Conclusions Uncontrolled hypertension was an independent determinant of clinically important nocturia in a large cross‐sectional community‐based study of non‐Hispanic black men aged 35 to 49 years. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unqiue identifier: NCT 02321618.
Collapse
Affiliation(s)
| | - Ning Li
- 2 Department of Biomathematics David Geffen School of Medicine at UCLA Los Angeles CA
| | | | | | - L Cindy Chang
- 2 Department of Biomathematics David Geffen School of Medicine at UCLA Los Angeles CA
| | | | | | | | | | | | | | - Florian Rader
- 1 Smidt Heart Institute at Cedars-Sinai Los Angeles CA
| | - Robert M Elashoff
- 2 Department of Biomathematics David Geffen School of Medicine at UCLA Los Angeles CA
| |
Collapse
|
2
|
Seeley A, Prynn J, Perera R, Street R, Davis D, Etyang AO. Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis. BMC Med 2020; 18:75. [PMID: 32216794 PMCID: PMC7099775 DOI: 10.1186/s12916-020-01530-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Accepted: 02/13/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The highest burden of hypertension is found in Sub-Saharan Africa (SSA) with a threefold greater mortality from stroke and other associated diseases. Ethnicity is known to influence the response to antihypertensives, especially in black populations living in North America and Europe. We sought to outline the impact of all commonly used pharmacological agents on both blood pressure reduction and cardiovascular morbidity and mortality in SSA. METHODS We used similar criteria to previous large meta-analyses of blood pressure agents but restricted results to populations in SSA. Quality of evidence was assessed using a risk of bias tool. Network meta-analysis with random effects was used to compare the effects across interventions and meta-regression to explore participant heterogeneity. RESULTS Thirty-two studies of 2860 participants were identified. Most were small studies from single, urban centres. Compared with placebo, any pharmacotherapy lowered SBP/DBP by 8.51/8.04 mmHg, and calcium channel blockers (CCBs) were the most efficacious first-line agent with 18.46/11.6 mmHg reduction. Fewer studies assessing combination therapy were available, but there was a trend towards superiority for CCBs plus ACE inhibitors or diuretics compared to other combinations. No studies examined the effect of antihypertensive therapy on morbidity or mortality outcomes. CONCLUSION Evidence broadly supports current guidelines and provides a clear rationale for promoting CCBs as first-line agents and early initiation of combination therapy. However, there is a clear requirement for more evidence to provide a nuanced understanding of stroke and other cardiovascular disease prevention amongst diverse populations on the continent. TRIAL REGISTRATION PROSPERO, CRD42019122490. This review was registered in January 2019.
Collapse
Affiliation(s)
- Anna Seeley
- Medical Research Council Unit Lifelong Health and Ageing at UCL, Department of Population Science and Experimental Medicine, University College London, London, UK.
- Nuffiend Department of Primary Health Care Sciences, Woodstock Road, Oxford, OX2 6GG, UK.
| | | | - Rachel Perera
- Medical Research Council Unit Lifelong Health and Ageing at UCL, Department of Population Science and Experimental Medicine, University College London, London, UK
| | - Rebecca Street
- Medical Research Council Unit Lifelong Health and Ageing at UCL, Department of Population Science and Experimental Medicine, University College London, London, UK
| | - Daniel Davis
- Medical Research Council Unit Lifelong Health and Ageing at UCL, Department of Population Science and Experimental Medicine, University College London, London, UK
| | - Anthony O Etyang
- Department of Epidemiology and Demography, KEMRI Wellcome Trust Research Programme, Kilifi, Kenya
| |
Collapse
|
3
|
Mengesha HG, Welegerima AH, Hadgu A, Temesgen H, Otieno MG, Tsegay K, Fisseha T, Getachew S, Merha Z, Tewodros H, Dabessa J, Gebreegzabher B, Petrucka P. Comparative effectiveness of antihypertensive drugs prescribed in Ethiopian healthcare practice: A pilot prospective, randomized, open label study. PLoS One 2018; 13:e0203166. [PMID: 30204768 PMCID: PMC6133365 DOI: 10.1371/journal.pone.0203166] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Accepted: 08/15/2018] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Previous research has been highly suggestive that patients of African ancestry are less responsive to beta-blockers and angiotensin converting enzyme inhibitors. However, clinical practice within Ethiopia has continued to recommend all drugs for treatment of hypertension despite the lack of evidentiary support. Therefore this study aims to compare the effectiveness of the three major antihypertensive drugs currently prescribed in an Ethiopian health care setting to further the potential for evidence based prescribing practices. METHODS A prospective, randomized, open label comparative study was used to determine the mean reduction in blood pressure (primary outcome) and assess cardiovascular events (secondary outcomes) among patients receiving one or more of three common antihypertensive drugs (i.e., nifedipine, hydrochlorothiazide, and enalapril) in routine clinical practice between November 2016 and April 2017. Patients were followed for three months. Analysis was based on an intention-to-treat approach. One way analysis of covariance was used to compare the difference in therapeutic effectiveness in reducing blood pressure. RESULT A total of 141 patients were randomized to one of three recipient groups-nifedipine (n = 47), enalapril (n = 47) or hydrochlorothiazide (n = 47). Three months after randomization, 44 patients in each group completed the follow-up. Patients randomized to nifedipine had significantly higher mean reduction in systolic blood pressure than those randomized to enalapril(p = 0.003) or hydrochlorothiazide(p = 0.036). The mean reduction in systolic blood pressure was -37.35(CI:-40, -34.2) in the nifedipine group; -30.3(CI: -33.5, -27.1) in patients receiving enalapril; and -32.1(CI:-35, -29.3) in patients assigned hydrochlorothiazide. However, nifedipine did not have a significance difference in reduction of mean diastolic blood pressure compared than those receiving enalapril (p = 0.57) or hydrochlorthiazide (p = 0.99). CONCLUSION This study revealed that amongst the three drugs nifedipine was found to be the most effective drug in reduction of systolic blood pressure. Hydrochlorothiazide and enalapril did not show a difference in reduction of mean blood pressure. Further, long term randomized trials are highly recommended to inform revision of Ethiopia-centric hypertension treatment guidelines.
Collapse
Affiliation(s)
| | | | - Abera Hadgu
- Departement of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia
| | - Haftom Temesgen
- School of Public Health, Mekelle University, Mekelle, Ethiopia
| | - Mala George Otieno
- College of Health Science, Department of Medical Biochemistry, Mekelle University, Mekelle, Ethiopia
| | - Kiflom Tsegay
- Adwa Hospital, Internal Medicine Unit, Adwa, Ethiopia
| | - Tedros Fisseha
- Adigrat Hospital, Internal Medicine Unit, Adigrat, Ethiopia
| | | | - Zekarias Merha
- Kidst Mariam Hospital, Internal Medicine Unit, Axum, Ethiopa
| | - Helen Tewodros
- Mekelle Hospital, Internal Medicine Unit, Mekelle, Ethiopia
| | - Jiksa Dabessa
- Ayder Referral Hospital, Internal Medicine Unit, Mekelle, Ethiopia
| | | | - Pammla Petrucka
- University of Saskatchewan, College of Nursing, Saskatchewan, Canada
- Adjunct Nelson Mandela African Institute of Science and Technology, Arusha, Tanzania
| |
Collapse
|
4
|
Nwachukwu DC, Eze AA, Nwachukwu NZ, Aneke EI, Agu PU, Azubike NC, Obika LF, Okoye OI. Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes. Malawi Med J 2018; 29:108-112. [PMID: 28955416 PMCID: PMC5610279 DOI: 10.4314/mmj.v29i2.6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background Amlodipine and hydrochlorothiazide (HCTZ) are commonly prescribed in Nigeria either as a monotherapy or in combination with other drugs. The present study was designed to investigate the antihypertensive efficacy of monotherapy with amlodipine or HCTZ and their effects on electrolyte profile in patients with mild to moderate hypertension. Methods A single-blind randomized clinical study was used; fifty patients newly diagnosed with mild to moderate hypertension (aged 33 to 60 years) were recruited and divided into two groups: amlodipine or hydrochlorothiazide each comprising of 25 subjects. The subjects received 5mg of amlodipine or 25mg of hydrochlorothiazide in their respective group once daily for 4 weeks. Blood pressure, serum and urine electrolytes were measured at baseline and weekly throughout the experiment. Results At the end of follow up, amlodipine reduced systolic and diastolic blood pressure significantly more (p<0.001) than HCTZ. At the end of follow up, blood pressure was reduced to normal in 80% of the subjects in amlodipine group compared to 50% in HCTZ. Amlodipine had no significant effect on electrolyte profile of subjects unlike HCTZ which significantly changed both their serum and urine electrolytes. Conclusions Monotherapy with amlodipine was more effective than HCTZ in black patients with mild to moderate hypertension and in addition maintained electrolyte balance.
Collapse
Affiliation(s)
- Daniel C Nwachukwu
- Department of Physiology, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria
| | - Anthonius A Eze
- Department of Medical Biochemistry, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria
| | - Nkiru Z Nwachukwu
- Department of Ophthalmolgy, University of Nigeria Teaching Hospital, Enugu, Nigeria
| | - Eddy I Aneke
- Department of Medicine, Enugu State University Teaching Hospital, Enugu, Nigeria
| | - Polycarp U Agu
- Department of Obstetrics and Gynaecology, University of Nigeria Teaching Hospital, Enugu, Nigeria
| | - Nkiru C Azubike
- Department of Medical Laboratory Science, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria
| | - Leonard Fo Obika
- Department of Physiology, School of Basic Medical Sciences, University of Benin, Benin City, Nigeria
| | - Onochie I Okoye
- Department of Ophthalmology, University of Nigeria Teaching Hospital, Enugu, Nigeria
| |
Collapse
|
5
|
Brewster LM, van Montfrans GA, Oehlers GP, Seedat YK. Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. Intern Emerg Med 2016; 11:355-74. [PMID: 27026378 PMCID: PMC4820501 DOI: 10.1007/s11739-016-1422-x] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Accepted: 02/22/2016] [Indexed: 02/06/2023]
Abstract
Despite the large differences in the epidemiology of hypertension across Europe, treatment strategies are similar for national populations of white European descent. However, hypertensive patients of African or South Asian ethnicity may require ethnic-specific approaches, as these population subgroups tend to have higher blood pressure at an earlier age that is more difficult to control, a higher occurrence of diabetes, and more target organ damage with earlier cardiovascular mortality. Therefore, we systematically reviewed the evidence on antihypertensive drug treatment in South Asian and African ethnicity patients. We used the Cochrane systematic review methodology to retrieve trials in electronic databases including CENTRAL, PubMed, and Embase from their inception through November 2015; and with handsearch. We retrieved 4596 reports that yielded 35 trials with 7 classes of antihypertensive drugs in 25,540 African ethnicity patients. Aside from the well-known blood pressure efficacy of calcium channel blockers and diuretics, with lesser effect of ACE inhibitors and beta-blockers, nebivolol was not more effective than placebo in reducing systolic blood pressure levels. Trials with morbidity and mortality outcomes indicated that lisinopril and losartan-based therapy were associated with a greater incidence of stroke and sudden death. Furthermore, 1581 reports yielded 16 randomized controlled trials with blood pressure outcomes in 1719 South Asian hypertensive patients. In contrast with the studies in African ethnicity patients, there were no significant differences in blood pressure lowering efficacy between drugs, and no trials available with mortality outcomes. In conclusion, in patients of African ethnicity, treatment initiated with ACE inhibitor or angiotensin II receptor blocker monotherapy was associated with adverse cardiovascular outcomes. We found no evidence of different efficacy of antihypertensive drugs in South Asians, but there is a need for trials with morbidity and mortality outcomes. Screening for cardiovascular risk at a younger age, treating hypertension at lower thresholds, and new delivery models to find, treat and follow hypertensives in the community may help reduce the excess cardiovascular mortality in these high-risk groups.
Collapse
Affiliation(s)
- Lizzy M Brewster
- Department of Vascular Medicine, F4-222, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
- Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Gert A van Montfrans
- Department of Vascular Medicine, F4-222, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
- Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Glenn P Oehlers
- Department of Cardiology, Academic Hospital of Paramaribo, Paramaribo, Suriname
| | - Yackoob K Seedat
- Nelson R Mandela School of Medicine, Faculty of Health Sciences, University of KwaZulu Natal, Private Bag. 7, Congella, 4013, Durban, South Africa
| |
Collapse
|
6
|
Brewster LLM, Kleijnen J, van Montfrans GA. WITHDRAWN: Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. Cochrane Database Syst Rev 2007; 2005:CD005183. [PMID: 17636788 PMCID: PMC10641648 DOI: 10.1002/14651858.cd005183.pub2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Black people have a greater prevalence of elevated blood pressure leading to excess morbidity and mortality. OBJECTIVES To systematically review the effects of different antihypertensive drugs on mortality, morbidity and blood pressure black adults with elevated blood pressure. SEARCH STRATEGY Medline, Embase, LILACS, African Index Medicus, the Cochrane Library November 2003; Pubmed September 2003 to March 2004. Searches were conducted without language restriction. SELECTION CRITERIA Randomised controlled trials of drugs versus placebo (blood pressure outcomes) or versus placebo or other drugs (morbidity and mortality outcomes). DATA COLLECTION AND ANALYSIS Two reviewers independently extracted data unblinded. Disagreements were resolved by discussion. Authors were contacted twice to obtain missing information. MAIN RESULTS Full reports or abstracts from more than 2900 references of papers yielded 30 trials considering 53 interventions with 8 classes of antihypertensive drugs in 20,006 black patients from Africa, the Caribbean, and the United States of America, aged 18 to >80 years. In one large trial the main morbidity and mortality outcomes did not differ significantly between initial treatment drug classes when drugs were added to reach goal blood pressures. However, the comparison ACE Inhibitors vs diuretic favoured the diuretic for stroke 1.40 [1.17 to 1.68]; combined CHD 1.15 [1.02 to 1.30] and combined CVD 1.19 [1.09 to 1.30] and the comparison alpha blocker vs diuretic favoured the diuretic for combined CVD 1.40 [1.25 to 1.57]. In addition, all comparisons for heart failure favoured diuretic (1.47 [1.24 to 1.74] vs calcium blocker; 1.32 [1.11 to 1.58] vs ACE Inhibitor; and 2.18 [1.73 to 2.74] vs alpha blocker. The results also showed a greater occurrence of diabetes with diuretics. No significant differences were detected between placebo and beta adrenergic blockers in the reduction of systolic blood pressure (weighted mean difference [95% CI], -3.52 [-7.50 to 0.46] mm Hg). In addition, ACE inhibitors did not significantly differ from placebo in achievement of goal diastolic blood pressure (risk difference [95% CI], 5% [-10% to 21%]). Calcium blockers, diuretics, centrally acting agents, alpha adrenergic blockers and angiotensin II antagonists were all more effective than placebo in reducing blood pressure in the pooled analyses. Only calcium blockers remained effective in all prespecified subgroups, including baseline diastolic blood pressure >109 mm Hg. AUTHORS' CONCLUSIONS When first-line drugs from different classes are compared in the treatment of black people, there is no evidence of differential effects on most mortality and morbidity outcomes. Those morbidity differences that were found favoured diuretics. Drugs differ in their ability to reduce blood pressure in black people. Calcium blockers were the only drug class that reduced blood pressure in all subgroups of black people including those with severe hypertension. Beta-blockers, angiotensin receptor blocker, alpha blockers and ACE Inhibitors were least good at reducing blood pressure in black adults.
Collapse
Affiliation(s)
- L L M Brewster
- Academic Medical Centre, Dept. of Internal Medicine F4-253, PO Box 22660, Amsterdam, Netherlands 1100 DD.
| | | | | |
Collapse
|
7
|
Adigun AQ, Ishola DA, Akintomide AO, Ajayi AAL. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. J Hum Hypertens 2003; 17:277-85. [PMID: 12714973 DOI: 10.1038/sj.jhh.1001538] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The current prescription patterns for essential hypertension and the efficacy, safety, tolerability and cost-effectiveness of the newer antihypertensive drugs were evaluated in Nigerian patients. The findings were compared with that of a previous study conducted in the same tertiary hospital 10 years earlier. A cross-sectional evaluation of blood pressure (BP) control in a hypertension clinic was undertaken among 150 Nigerian patients aged 61 +/- 12 years (55% females), with a duration of treatment on a particular drug class or combination of 9 +/- 3 months. The initial blood pressure was 176 +/- 20/108 +/- 11 mmHg and 22% of the patient had concurrent diabetes mellitus. Thiazide diuretics (D) alone or in combination remained the most commonly prescribed drugs in 56% of all patients. There were significant increases in the prescriptions of calcium channel blockers (CCBs) (51%), P < 0.0001, and ACE-inhibitors (ACEIs) (24%), P < 0.0001, but a slight reduction in the use of methyldopa, and fixed drug combinations (P < 0.01) compared to the previous study. The fall in systolic blood pressure on D (r = 0.65, P < 0.001) or CCB (r = 0.48, P < 0.02) was significantly correlated with the initial systolic blood pressure, but not age. More patients achieved normotension BP < 140/90 mmHg on CCB monotherapy (71%), than D monotherapy (56%). Combination therapy with ACEIs + D or methyldopa+thiazides normalized BP in 63 and 68%, respectively. Pulse pressure, a surrogate marker for cardiovascular complications and mortality in essential hypertension, was significantly reduced (P < 0.01) equally by all treatments, with 95% confidence intervals ranging from -28 to -1 mmHg. However, hypertensive-diabetic (HT-DM) patients (n = 33) exhibited no significant change in pulse pressure in response to treatment. Adverse drug reactions that occurred in 11% were impotence or postural dizziness with D, headache and pitting oedema with CCB, and dry cough with ACEI. Pharmaco-economic comparison of the drug classes revealed that for every US dollar (dollar) spent per month, the percentage of treated patients attaining normotension was 18.6 for D, 4.73 for CCB, 3.5 for ACEI + D and 13.6 for methyldopa + thiazides. A combination of ACEI + CCB or D was the preferred treatment for hypertensive-diabetic Nigerians, but only 24% attained a BP < 130/85 mmHg. These results demonstrate a shift in trend to a more rational and efficacious treatment of hypertension over a 10 year period. This may be associated, at least in part, with the intensive and continuous education of the prescribers in rational drug use and the introduction of a hospital formulary. Methyldopa is still a highly efficacious and cost-effective drug in this population. Black HT-DM Africans still constitute a subgroup who not only require more and costlier antihypertensive drugs, but whose BP control is suboptimal, and exhibit a poor therapeutic response to other risk factors (pulse pressure) that constitute a continuing risk for cardiovascular mortality.
Collapse
Affiliation(s)
- A Q Adigun
- Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, USA
| | | | | | | |
Collapse
|
8
|
Mabadeje AF. WHO-ISH Guidelines for the management of hypertension: implementation in Africa--the Nigerian experience. Clin Exp Hypertens 1999; 21:671-81. [PMID: 10423091 DOI: 10.3109/10641969909060998] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A 1990-91 country-wide survey in Nigeria showed the prevalence of hypertension to be 11.2% in those aged 15 years and above. The management, however, has been shown to be inadequate. At the instance of the Nigerian Hypertension Society a Consensus Meeting of National Medical Societies and other interest groups produced in 1996 Guidelines for the Management of Hypertension in Nigeria. Medical societies and the pharmaceutical industry have tried to increase awareness of the condition and its control through lectures, seminars, sponsor of essay competitions among secondary school and university students as well as canvassing against cigarette advertising and smoking in public places. However, their efforts are thwarted by luring advertisements by multinational tobacco companies driven from developed countries by anti-tobacco lobbies and legislation. A questionnaire survey showed that no other African country had produced similar guidelines in the past five years. In Sub-Saharan Africa there appears to be negligible implementation of the WHO-ISH Guidelines.
Collapse
Affiliation(s)
- A F Mabadeje
- Nigerian Hypertension Society, Dialysis Centre, Lagos University Teaching Hospital, Nigeria
| |
Collapse
|
9
|
Stason WB, Schmid CH, Niedzwiecki D, Whiting GW, Luo D, Ross SD, Chalmers TC. Safety of Nifedipine in Patients With Hypertension. Hypertension 1997. [DOI: 10.1161/hyp.30.1.7/a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- William B. Stason
- From the Harvard School of Public Health (W.B.S.); MetaWorks, Inc (W.B.S., D.N., G.W.W., D.L., S.D.R., T.C.C.); Tufts University/New England Medical Center (C.H.S.); and Tufts University (T.C.C.), Boston, Mass
| | - Christopher H. Schmid
- From the Harvard School of Public Health (W.B.S.); MetaWorks, Inc (W.B.S., D.N., G.W.W., D.L., S.D.R., T.C.C.); Tufts University/New England Medical Center (C.H.S.); and Tufts University (T.C.C.), Boston, Mass
| | - Donna Niedzwiecki
- From the Harvard School of Public Health (W.B.S.); MetaWorks, Inc (W.B.S., D.N., G.W.W., D.L., S.D.R., T.C.C.); Tufts University/New England Medical Center (C.H.S.); and Tufts University (T.C.C.), Boston, Mass
| | - Gregory W. Whiting
- From the Harvard School of Public Health (W.B.S.); MetaWorks, Inc (W.B.S., D.N., G.W.W., D.L., S.D.R., T.C.C.); Tufts University/New England Medical Center (C.H.S.); and Tufts University (T.C.C.), Boston, Mass
| | - Donghan Luo
- From the Harvard School of Public Health (W.B.S.); MetaWorks, Inc (W.B.S., D.N., G.W.W., D.L., S.D.R., T.C.C.); Tufts University/New England Medical Center (C.H.S.); and Tufts University (T.C.C.), Boston, Mass
| | - Susan D. Ross
- From the Harvard School of Public Health (W.B.S.); MetaWorks, Inc (W.B.S., D.N., G.W.W., D.L., S.D.R., T.C.C.); Tufts University/New England Medical Center (C.H.S.); and Tufts University (T.C.C.), Boston, Mass
| | - Thomas C. Chalmers
- From the Harvard School of Public Health (W.B.S.); MetaWorks, Inc (W.B.S., D.N., G.W.W., D.L., S.D.R., T.C.C.); Tufts University/New England Medical Center (C.H.S.); and Tufts University (T.C.C.), Boston, Mass
| |
Collapse
|
10
|
Stason WB, Schmid CH, Niedzwiecki D, Whiting GW, Caubet JF, Luo D, Ross SD, Chalmers TC. Safety of nifedipine in patients with hypertension: a meta-analysis. Hypertension 1997; 30:7-14. [PMID: 9231814 DOI: 10.1161/01.hyp.30.1.7] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Our objective was to compare cardiovascular event rates in patients with mild or moderate hypertension who received nifedipine with active drug controls. We performed a MEDLARS search using the MeSH heading "hypertension" and the text word "nifedipine" to identify all articles that were published between 1966 and August 1995 in English, French, German, Italian, and Spanish languages and that involved human subjects. The computerized search was supplemented by a manual search of article bibliographies. Review of 1880 citations revealed 98 randomized controlled clinical trials that met protocol criteria. Articles were extracted independently by two doctors who were blinded for author, institution, and treatment regimen, using a structured, pretested extraction form. Differences of opinion were resolved by consensus. Fourteen events occurred in 5198 exposures (0.27%) to nifedipine and 24 events in 5402 exposures (0.44%) to other active drug controls. Unadjusted odds ratios for nifedipine versus controls were 0.49 (95% confidence interval [CI], 0.22-1.09) for definitive events (death, nonfatal myocardial infarction or stroke, revascularization procedure) and 0.61 (95% CI, 0.31-1.17) for all events (definitive plus increased angina). The odds ratio for nifedipine monotherapy (sustained- or extended-release in 91% of exposures) was nonsignificantly higher for definitive and all events (odds ratio, 1.40; 95% CI, 0.49-4.03 and odds ratio, 1.39; 95% CI, 0.59-3.32, respectively). The odds ratio for nifedipine in combination with another drug was significantly lower for definitive and all events (odds ratio, 0.09; 95% CI, 0.01-0.66 and odds ratio, 0.15; 95% CI, 0.03-0.65, respectively). Differences in odds ratio for nifedipine monotherapy and combined therapy were statistically significant (P=.02 for definitive events and P=.001 for all events). Results support the safety of sustained- and extended-release nifedipine in the treatment of mild or moderate hypertension when it is used in combination with other drugs.
Collapse
Affiliation(s)
- W B Stason
- Harvard School of Public Health, Boston, Mass., USA
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Isah AO, Obasohan AO, Oyewo EA, Ohaju-Obodo J. Amlodipine versus nifedipine in the treatment of mild-to-moderate hypertension in black Africans. Curr Ther Res Clin Exp 1996. [DOI: 10.1016/s0011-393x(96)80038-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
12
|
Ajayi AA, Raji MA. Acute cardiovascular effects of the concurrent administration of enalapril, prazosin or amlodipine in healthy Nigerians. Int J Cardiol 1994; 44:79-84. [PMID: 8021054 DOI: 10.1016/0167-5273(94)90070-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The acute circulatory effects of the combination of prazosin 1 mg, enalapril 10 mg or amlodipine 5 mg were evaluated and compared in a placebo controlled, randomised, double blind, latin-square, cross-over study in 8 normotensive healthy Nigerians. Supine and erect blood pressure were reduced by the active treatment combinations (F = 8.8, P = 0.0006, analysis of variance). In all, the onset of blood pressure fall was within 2 h, with a peak reduction at 4-6 h and persisting for at least 12 h. The combination of converting enzyme inhibitor and alpha blocker, however, caused a significantly greater hypotensive action than the other combinations (P < 0.05, analysis of variance). There was a modest reflex tachycardia in the erect position on all treatments (P = 0.008). Cardiac autonomic reflexes or left ventricular echocardiographic indices were unaffected by the drug combinations. The haemodynamic effect of enalapril plus prazosin combination, which separately cause little hypotensive effect in Africans, may reflect an important pharmacodynamic interaction between alpha 1 and angiotensin II vascular receptors. All combinations lower blood pressure and warrant further study in Nigerian hypertensives. However, the enalapril plus prazosin combination caused the greatest blood pressure fall, and caution is indicated during their concurrent use, owing to enhanced first dose hypotension.
Collapse
Affiliation(s)
- A A Ajayi
- Department of Medicine, Faculty of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria
| | | |
Collapse
|
13
|
Marín J. Mechanisms involved in the increased vascular resistance in hypertension. JOURNAL OF AUTONOMIC PHARMACOLOGY 1993; 13:127-76. [PMID: 8486727 DOI: 10.1111/j.1474-8673.1993.tb00264.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- J Marín
- Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma, Madrid, Spain
| |
Collapse
|
14
|
Daniels SR, Loggie JM. Hypertension in Children and Adolescents. PHYSICIAN SPORTSMED 1992; 20:96-110. [PMID: 27424643 DOI: 10.1080/00913847.1992.11710276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
In brief For hypertensive children and adolescents who participate in sports, hygienic interventions may already be adequate-or may be unachievable. Yet, the decision to initiate pharmacotherapy is difficult. Physicians must weigh factors such as the presence of end-organ damage or a family history of early hypertensive complications with possible adverse effects of antihypertensive drugs, including depressant effects on the heart and reduced exercise tolerance. The authors favor long-lasting ACE inhibitors or calcium channel blockers, which usually do not alter heart rate and are relatively free of side effects.
Collapse
|
15
|
M'Buyamba-Kabangu JR, Tambwe M. The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks. Cardiovasc Drugs Ther 1990; 4 Suppl 2:389-94. [PMID: 1980202 DOI: 10.1007/bf02603182] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The data on treatment of hypertension in black patients with beta-adrenoceptor blockers (BB) or calcium-entry blockers (CEB) have been reviewed. There is much evidence that in monotherapy BB are no better than inert placebo for the majority of hypertensive black patients. Their hypotensive action in blacks is less than that induced by other antihypertensive agents, mainly diuretics. Comparative evaluation of the responsiveness of blacks, whites, and Indians to BB therapy showed a poorer control of blood pressure (BP) among blacks than among nonblacks. However, when combined with diuretic therapy, BBs are equipotent in blacks and whites. The reasons for the hyporesponsiveness of black patients to BB therapy are not fully understood. On the other hand, CEBs appear to be as efficacious as diuretic therapy in hypertensive blacks. In addition, they lower blood pressure to the same extent in black and white patients. They are also proven to be effective adjunctive therapy to diuretics for hypertension in blacks. The reason for the better responsiveness of blacks to CEB therapy might include the severity of hypertension in blacks, their low plasma renin, their blunted sympathetic activity, and their high intracellular sodium concentration.
Collapse
|
16
|
Ajayi AA, Oyewo EA, Ladipo GO, Akinsola A. Enalapril and hydrochlorothiazide in hypertensive Africans. Eur J Clin Pharmacol 1989; 36:229-34. [PMID: 2545454 DOI: 10.1007/bf00558152] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The antihypertensive efficacy both of angiotensin converting enzyme (ACE) inhibitors and thiazide diuretics has been claimed to be influenced by plasma renin activity, which declines with age and is low in blacks. In a double-blind, placebo-controlled, double-dummy, randomized, parallel-group preliminary study, the antihypertensive efficacy and tolerability of the ACE inhibitor enalapril (20 mg day-1) and hydrochlorothiazide (50 mg day-1) were evaluated and compared for 4 weeks in 20 African patients with essential hypertension. The two groups had similar baseline clinical features and serum Na+ and K+ levels. Hydrochlorothiazide caused a significant and sustained fall in erect blood pressure with a reflex tachycardia. Enalapril exerted only a modest antihypertensive action, but significantly reduced erect heart rate. Direct comparison of hydrochlorothiazide- and enalapril-induced hypotension suggested a greater fall in subjects on the thiazide. The 95% confidence limits for the thiazide-enalapril difference in antihypertensive action at the end of the study was 39.5 to -7.5 mm Hg systolic and 22.0 to -6.6 mm Hg diastolic. The maximal blood pressure fall after hydrochlorothiazide was positively correlated with age (r = 0.50; p less than 0.05), whilst that of enalapril was inversely related age to (r = -0.57, p less than 0.05). The results are compatible with the notion that ACE inhibitor monotherapy may be less effective than thiazide diuretic treatment in African and black patients with essential hypertension. The findings also support the concept that age and racial factors may influence the response to antihypertensive treatment.
Collapse
Affiliation(s)
- A A Ajayi
- Department of Medicine, Faculty of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria
| | | | | | | |
Collapse
|
17
|
Opie LH. Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications. Cardiovasc Drugs Ther 1988; 1:625-56. [PMID: 3154329 DOI: 10.1007/bf02125750] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The major antihypertensive mechanism of calcium antagonists is by decreasing the systemic vascular resistance, modified by the counter-regulatory responses of the baroreflexes and the renin-angiotensin-aldosterone system. In severe hypertension, the concept that calcium overload of the vascular myocyte could precipitate or aggravate peripheral vasoconstriction provides a logical basis for the use of these agents as first choice therapy; nifedipine, especially, has been well tested. As monotherapy for mild to moderate hypertension each of the three first-generation agents compares well with beta-blockers. Calcium antagonists may have a special role in the therapy of certain patient groups (elderly, black) or in those subjects whose life style involves intense physical or mental exertion (hemodynamics better maintained than with beta-blockade) or in patients with early end-organ damage such as left ventricular hypertrophy or renal insufficiency. However, the goal blood pressure may not be reached during monotherapy so that drug combinations may be required. Further indications for these compounds are as follows. Verapamil and diltiazem are frequently used in supraventricular tachycardias including acute and chronic atrial fibrillation. In the arrhythmias of the Wolff-Parkinson-White syndrome, there is the potential danger of provocation of anterograde conduction. Further indications for calcium antagonists, still under evaluation, include congestive heart failure (controversial), hypertrophic cardiomyopathy (verapamil), primary pulmonary hypertension (high doses required), Raynaud's phenomenon (nifedipine and diltiazem effective), peripheral vascular disease (proof not yet documented), cerebral insufficiency and subarachnoid hemorrhage (nimodipine promising), migraine, exertional bronchospasm, renal disease, atherosclerosis (experimental), and primary aldosteronism (nifedipine inhibits aldosterone release). Second-generation agents include dihydropyridines, such as nitrendipine, nicardipine, felodipine, amlodipine, nisoldipine, nimodipine, and isradipine. From these will be selected agents that are longer acting and provide higher vascular selectivity. New preparations of existing agents include slow-release formulations of nifedipine, verapamil, and diltiazem. Minor side effects include those caused by vasodilation (flushing and headaches), constipation (verapamil), and ankle edema. Serious side effects are rare and result from improper use of these agents, as when intravenous verapamil is given to patients with sinus or atrioventricular nodal depression from drugs or disease, or nifedipine to patients with aortic stenosis. The potential of a marked negative inotropic effect is usually offset by afterload reduction, especially in the case of nifedipine. Yet caution is required when calcium antagonists, especially verapamil, are given to patients with myocardial failure unless caused by hypertensive heart disease. Drug interactions of calcium antagonists occur with other cardiovascular agents such as alpha-adrenergic blockers, beta-adrenergic blockers, digoxin, quinidine, and disopyramide.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- L H Opie
- University of Cape Town Medical School, Republic of South Africa
| |
Collapse
|